Jenscare Scientific
With a focus on the R&D, production, sales and service of minimally invasive interventional therapies for structural heart diseases, we are dedicated to providing patients and physicians with comprehensive innovative solutions.
Scroll
Corporate Profile

Jenscare Scientific Co., Ltd. is a medical device company dedicated to the development of innovative solutions for structural heart disease. Our Company was founded in November 2011. Since then we have independently developed a series of innovative products targeting tricuspid valve diseases, mitral valve diseases, aortic valve diseases, and heart failure. And we are expanding our product candidates so as to provide "heart power" for patients around the world who do not have access to effective treatment options.

Development path
2011
2011年
2014
2014年
2016
2016年
2017
2017年
2018
2018年
2019
2019年
2020
2020年
2021
2021年
2022
2022年
2023
2023年

Jenscare Scientific Co., Ltd. was formally established on November 8, 2011

We initiated the research and development of Ken-Valve, AnchorValve, LuX-Valve and MitraPatch

Our technology “animal-derived tissues or organs immunogenicity elimination and anti-calcification value technologies” was enlisted in the National Key Research and Development Program of the Ministry of Science and Technology

We initiated the research and development of KenFlex

We completed the implantation of LuX-Valve and Ken-Valve in the first human subject

We initiated the research and development of LuX-Valve Plus

We completed our Series A Financing and raised RMB50 million

LuX-Valve was admitted into the Green Path by the NMPA

We initiated the multi-center feasibility clinical trial for Ken-Valve

LuX-Valve, was awarded the second prize in the China Innovation and Entrepreneurship Competition in October

LuX-Valve was a finalist in the TCT Shark Tank competition globally, being the first Chinese product to be enlisted in this competition

We initiated the research and development of JensT-Clip and JensClip

We completed the multi-center feasibility clinical trial for LuX-Valve

We were awarded the Subramanian Innovation Award by the International Society for Minimally Invasive Cardiothoracic Surgery (“ISMICS”)

We completed the Equity Swap and Ningbo DioChange became our wholly-owned subsidiary under merger accounting, which developed our business in heart failure

We initiated the confirmatory clinical trial for LuX-Valve

We completed our Series B Financing and raised RMB400 million

We initiated the confirmatory clinical trial for Ken-Valve

We completed our Series C Financing and raised USD163,636,30. We introduced a number of internationally renowned professional investors

We completed the subject enrollments of confirmatory clinical trials of LuX-Valve

LuX-Valve was designated as a Breakthrough Device by U.S. FDA

We are in the process of initiating the clinical trial for LuX-Valve Plus for CE Marking in Europe

We initiated the feasibility clinical trial for JensClip in China

Procedures implementing LuX-Valve Plus have also been successfully performed at St. Paul's Hospital in Canada on eleven subjects

Procedures implementing LuX-Valve Plus have been successfully performed for the first time in Europe at the University Hospital of Bordeaux in France, followed by another such procedure successfully performed in Germany

We completed the subject enrollments of confirmatory clinical trial of Ken-Valve

LuX-Valve's registration application was accepted by NMPA as scheduled, and entered registration review stage successfully

LuX-Valve Plus completed confirmatory clinical trial; is under enrollment of CE registration clinical trail; submitted pre-submission for EFS and was accepted by FDA

LuX-Valve Plus was selected into Total Product Life Cycle Advisory Program (TAP) by FDA

LuX-Valve Plus was selected for Expert Panel Scientific Advice Pilot in Europe by EMA

LuX-Valve Plus completed a series of fee-for-service compassionate use treatments in the Asia-Pacific region

Ken-Valve entered registration review stage successfully, realized the one and only valve product being selected for the NMPA priority approval process

JensClip completed feasibility clinical trial and is under enrollment of confirmatory clinical enrollment

SimuLock completed its first enrollment of NMPA confirmatory clinical trial

OmniSeal completed its first clinical implantation

Company Honor
Subramanian Innovation Award 2020 from International Society for Minimally Invasive Cardiothoracic Surgery (“ISMICS”)
EuroPCR2021 European Annual Conference on Cardiovascular Interventions
TCT 2019, San Francisco, USA
CSI 2019, Frankfurt, Germany
2nd prize of the Biomedical Industry Growth Group of the 8th China Innovation and Entrepreneurship Competition
China Heart Congress (CHC) 2021 and the 6th China Vascular Congress (CVC)
Future Medical Top 100 2019 Top 100 Innovative Devices in China
Xinxin Cup 2019 · Top 10 Cardiovascular Innovation Technologies in China Transcatheter Tricuspid Valve Replacement System
Most Influential List of China's Pharmaceutical Industry 2018 Chinese Medical Device Innovation Enterprise
Finalist of China Innovation and Entrepreneurship Competition 2019 1st Prize of Materials and Accessories
Semi-finalist of China Innovation and Entrepreneurship Competition 2019 1st Prize of Materials and Accessories
The Research and Industrialization Project of New Transcatheter Heart Valve Replacement and Repair Devices was included in the Ningbo Science and Technology Innovation 2025 Major Projects
Excellent Enterprise (Growth Group) of the 8th China Innovation and Entrepreneurship Competition
Excellent Enterprise (Growth Group) of the 6th China Innovation and Entrepreneurship Competition
Innovation Star in the Competition 2019 - Looking for the Enterprise of the Most Investment Value in Ningbo
Excellent Enterprise in Ningbo Area of the 8th China Innovation and Entrepreneurship Competition
Excellent Enterprise in Ningbo Area of the 6th China Innovation and Entrepreneurship Competition
1st Prize in Ningbo Area of the 8th China Innovation and Entrepreneurship Competition
3rd Prize in Ningbo Area of the 6th China Innovation and Entrepreneurship Competition
Best Innovative Medical Device Enterprise in the 5th Medical and Health Investment Excellence List 2021
Finalist of China Innovation and Entrepreneurship Competition 2018 (Eastern Competition Area)
Enterprise Technology Innovation Team in Ningbo Hangzhou Bay New Zone 2014
Silver Award of Innovation and Development Model 2021
Zhejiang Science and Technology Small and Medium Enterprise (SME) Certificate
World Young Scientists Summit 2019 (Wenzhou) - Letter of Appreciation